Abeona Therapeutics (NASDAQ:ABEO) Director Eric Crombez Sells 16,284 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Eric Crombez sold 16,284 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $82,885.56. Following the completion of the transaction, the director owned 63,456 shares of the company’s stock, valued at $322,991.04. This represents a 20.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Abeona Therapeutics Stock Performance

ABEO stock traded up $0.08 during midday trading on Monday, reaching $5.17. 756,510 shares of the company’s stock traded hands, compared to its average volume of 1,266,662. The firm has a market capitalization of $280.17 million, a PE ratio of 4.20 and a beta of 1.12. The company has a 50-day moving average price of $5.15 and a two-hundred day moving average price of $5.60. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, equities analysts anticipate that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABEO. Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Abeona Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Hedge Funds Weigh In On Abeona Therapeutics

A number of large investors have recently modified their holdings of ABEO. AIGH Capital Management LLC bought a new position in Abeona Therapeutics during the fourth quarter valued at approximately $10,540,000. PVG Asset Management Corp purchased a new stake in shares of Abeona Therapeutics in the 4th quarter valued at $66,000. Aberdeen Group plc purchased a new stake in shares of Abeona Therapeutics in the 4th quarter valued at $3,248,000. SG Americas Securities LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at $57,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in Abeona Therapeutics in the 3rd quarter worth $64,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.